Back to Journals » ClinicoEconomics and Outcomes Research » Volume 10

Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England

Total article views   HTML views PDF downloads Totals
12,959 Dovepress* 10,206+ 1,713 11,919
PubMed Central* 2,753 519 3,272
Totals 12,959 2,232 15,191
*Since 23 April 2018
Total mentioned Facebook Delicious Reddit Twitter Others
4 0 0 0 2 2

View citations on PubMed and Google Scholar